Enterin
Philadelphia
About Enterin
We are a clinical stage biopharmaceutical company engaged in the discovery and development of synthetic derivatives of newly discovered endogenous hormones that target misfolded proteins, including alpha-synuclein in Parkinson’s Disease, or PD, amyloid beta and tau in Alzheimer’s Disease, or AD, as well as targeting insulin resistance which is central to the pathology of Type 2 Diabetes, or T2D, and AD. Our vision is to prevent the onset of these neurodegenerative and metabolic disorders, as well as to slow their progression.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $81.6M
- Last round: Series Unknown (Dec 2023)
- Website: enterin.com
- Phone: 215-372-8031
Industries & Categories
Biopharma, Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/enterin-116283 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.